Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - Shire plc | dp60259_8k.htm |
Exhibit 99.1
Press Release www.shire.com |
 |
Total Voting Rights
October 1, 2015 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”), in accordance with the Financial Conduct Authority's (the “FCA”) Disclosure and Transparency Rule 5.6.1R, notifies the market of the following:
As at September 30, 2015, the Company’s issued ordinary share capital comprised 592,061,538 ordinary shares of 5 pence each with voting rights and a further 8,527,703 ordinary shares held in treasury.
Therefore the total number of voting rights in the Company is 592,061,538. This is the figure which should be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.
Oliver Strawbridge
Senior Assistant Company Secretary
For further information please contact:
| Investor Relations | ||
| Matthew Osborne | mattosborne@shire.com | +1 781 482 9502 |
| Sarah Elton-Farr | seltonfarr@shire.com | +44 1256 894157 |
NOTES TO EDITORS
Shire enables people with life-altering conditions to lead better lives.
Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.
We focus on providing treatments in Rare Diseases, Neuroscience, Gastrointestinal and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmics.
www.shire.com
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX